Ivacaftor-D9 (CTP-656) is a potentCFTR modulatorand exhibits anEC₅₀value of 255 nM forCFTRpotentiation in G551D/F508del HBE Cells. Ivacaftor-D9 acts as an orally active and improved deuterated Ivacaftor analog for cystic fibrosis research^[1].

In PK study, CTP-656 (oral gavage; 10 mg/kg; single dose) shows a superior pharmacokinetic profile, The plasma levels of compound were measured over 72 hours,exhibits the parameters C_max, AUC_{0-24 hr}, C_24hrand t_1/2of 1970 ng/ml (15%), 24,260 hr*ng/ml(17%), 413 ng/ml (19%) and 13.9 hours, respectively in Male Sprague-Dawley rats.
CTP-656 (oral gavage; 3 mg/kg; single dose) exhibits the parameters C_max, AUC_{0-24 hr}, C_24hrand t_1/2of 3643 ng/ml (9%), 49,782 hr*ng/ml(31%), 1418 ng/ml (31%) and 22.8 hours, respectively in Male Beagle Dogs (3.0 mg/kg).

401.55

C₂₄H₁₉D₉N₂O₃

1413431-07-8

依伐卡托 D9

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.